Glycorex Transplantation AB (publ)
Research Glycorex Transplantation AB (publ) (O33) on Bullrun: market cap EUR 9.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerO33
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 9.30M
- Financial periodQ1 2026
- RevenueSEK 8.72M
- Net income-SEK 3.52M
- Free cash flow-SEK 1.01M
- Gross margin75.1%
Valuation Snapshot
latest market cap is EUR 9.30M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 38.84M | -SEK 7.72M | SEK 2.22M | 82.8% | -0.09 | SEK 10.16M | SEK 6.99M | SEK 34.54M |
| FY2024 | SEK 35.16M | -SEK 10.94M | SEK 101.00K | n/a | -0.15 | SEK 5.77M | SEK 279.00K | SEK 33.11M |
| FY2023 | SEK 29.96M | -SEK 30.36M | -SEK 12.53M | n/a | -0.41 | SEK 12.89M | SEK 932.00K | SEK 44.04M |
| FY2022 | SEK 36.12M | -SEK 8.58M | -SEK 1.48M | n/a | -0.12 | SEK 32.63M | SEK 622.00K | SEK 74.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 9.30M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Glycorex Transplantation AB (publ)
Glycorex Transplantation AB (publ), a medical technology company, research, develops, manufactures, markets, and sells products in the field of organ transplantation or related areas. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company's principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transplantation procedures.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Glycorex Transplantation AB (publ)'s market cap?
Glycorex Transplantation AB (publ)'s market capitalization is EUR 9.30M.
What does Glycorex Transplantation AB (publ) do?
Glycorex Transplantation AB (publ), a medical technology company, research, develops, manufactures, markets, and sells products in the field of organ transplantation or related areas. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company's principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transplantation procedures. It serves in the United Kingdom, Australia, Scandinavia, Spain, Germany, and Austria.